# Novavax to Participate in 2026 Jefferies Global Healthcare Conference - Jun 1, 2026
Canonical URL: https://biopharmsignal.com/news/NVAX/novavax-to-participate-in-2026-jefferies-global-healthcare-conference-jun-1-2026-13dbcea1
Ticker: NVAX
Company: Novavax
Source: Novavax
Published: 2026-07-09 12:00 EST
Original Source URL: https://ir.novavax.com/press-releases
## Summary

Novavax, Inc. (Nasdaq: NVAX) today announced it will participate in the 2026 Jefferies Global Healthcare Conference. Conference Details: Fireside Chat Date: Thursday, June 4, 2026 Time: 10:30 –...

## Article Body
GAITHERSBURG, Md. , June 1, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will participate in the 2026 Jefferies Global Healthcare Conference.

Conference Details:

Fireside Chat

Date:

Thursday, June 4, 2026

Time:

10:30 – 11:00 a.m. Eastern Time

Location:

New York, NY

Recordings A webcast of the fireside chat will be available on the Events & Presentations page of the Company's website at ir.novavax.com . A replay of the webcast will be available for 30 days.

About Novavax Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including its Matrix-M ® adjuvant and protein-based nanoparticles. The Company's corporate growth strategy is designed to deliver value via three key strategic pillars: partnering its technology, capital-efficient research and development (R&D) innovation and a lean and efficient operating model. This includes maximizing impact through partnerships for its marketed products (Nuvaxovid, R21/Matrix-M™), Matrix technology and R&D assets. Please visit novavax.com and LinkedIn for more information.

Contacts: Investors Jim Kelly 844-668-2829 [email protected]

Media Yvonne Sprow 844-264-8571 [email protected]

SOURCE Novavax, Inc.
## Recent Company News
- 2026-07-09 12:00 EST — [Novavax Reports First Quarter 2026 Financial Results and Operational Highlights - May 6, 2026](https://biopharmsignal.com/news/NVAX/novavax-reports-first-quarter-2026-financial-results-and-operational-highlights--a11612f1) — Source: Novavax
- 2026-07-09 12:00 EST — [Novavax to Participate in BofA Securities 2026 Health Care Conference - May 7, 2026](https://biopharmsignal.com/news/NVAX/novavax-to-participate-in-bofa-securities-2026-health-care-conference-may-7-2026-b9786971) — Source: Novavax
- 2026-07-09 12:00 EST — [Novavax to Participate in 2026 Jefferies Global Healthcare Conference - Jun 1, 2026](https://biopharmsignal.com/news/NVAX/novavax-to-participate-in-2026-jefferies-global-healthcare-conference-jun-1-2026-13dbcea1) — Source: Novavax
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)